Clinical trials: Oral Phase
Psoriasis Vulgaris
LEO 32731 - A Phase I Study in Healthy Subjects
LEO 32731 ("Study Drug") is an investigational drug which is being developed by LEO Pharma A/S ("the Sponsor") for treatment of psoriasis.
- Trial name
- NCT02514694
- Testing
- LEO32731
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Pancreatic Cancer
A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer
The primary purpose of this study is to determine the safety and recommended dose level (RDL) of BLEX 404 Oral Liquid combined with Gemcitabine monotherapy in a 28-day schedule.The secondary purpose is to assess the efficacy and…
- Trial name
- NCT03301805
- Testing
- BLEX 404
- Volunteers
- 40 people
- Sponsor
- Rgene Corporation
Healthy
A Study to Understand the Effect of a Study Medicine Called ARV-471 on Dabigatran Etexilate in Healthy Adults
The purpose of this study is to understand if ARV-471 affects how a medicine called, dabigatran etexilate, gets absorbed or processed into the body in healthy adults.
- Trial name
- NCT05673889
- Testing
- ARV-471, Dabigatran etexilate
- Where
- Belgium
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hypertension
Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Patients With Stage II Hypertension
The purpose of this study is to evaluate the blood pressure lowering effects of a valsartan/amlodipine combination treatment and amlodipine monotherapy for the treatment of stage II hypertensive patients (MSSBP ≥ 160 mmHg).
- Trial name
- NCT00350168
- Testing
- valsartan + amlodipine
- Where
- United States
- Volunteers
- 647 people
- Sponsor
- Novartis
Pain
Pharmacokinetics & Safety of Diclofenac Potassium Oral Solution in Ped. Subjects (2-12 Yrs) With Mild-Mod. Acute Pain
As part of the Pediatric Research Equity Act (PREA) commitment, the objectives of the study are to characterize the pharmacokinetic (PK) profile and to determine the safety and tolerability of diclofenac potassium oral solution…
- Trial name
- NCT02287350
- Testing
- diclofenac potassium oral solution
- Where
- 5 sites in United States
- Volunteers
- 51 people
- Sponsor
- Depomed
Oral Squamous Cell Carcinoma (OSCC), Neoadjuvant Chemoimmunotherapy
Adebrelimab Combined With Carboplatin and Albumin-bound Taxanol in the Treatment of Resectable Locally Advanced Oral Squamous Cell Carcinoma Cardiac, Randomized, Phase II Exploratory Study
Neoadjuvant immunochemotherapy can effectively increase the postoperative pathological complete response rate, improve the survival rate of patients, and reduce the risk of recurrence in oral squamous cell carcinoma (OSCC).
- Trial name
- NCT07137858
- Testing
- Preoperative neoadjuvant immunotherapy chemotherapy, Two courses of preoperative neoadjuvant immunotherapy chemotherapy, Three courses of preoperative neoadjuvant immunotherapy chemotherapy
- Volunteers
- 70 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Infections, Rotavirus
Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
The purpose of this study is to complete the total safety database size for GlaxoSmithKline Biologicals' (GSK's) human rotavirus (HRV) vaccine across the Porcine circovirus (PCV)-free development plan.
- Trial name
- NCT03954743
- Testing
- PCV-free liquid formulation of GSK's oral live attenuated HRV vaccine, Lyophilized formulation of GSK's oral live attenuated HRV vaccine
- Where
- 37 sites in United States, Canada and 3 more
- Volunteers
- 1,351 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
A Study to Evaluate the Effect of ASP1941 in Adult Patients With Type 2 Diabetes Mellitus
Evaluate the efficacy, safety, and tolerability of multiple doses of ASP1941 compared to placebo over 12 weeks of therapy in adult patients with type 2 diabetes mellitus.
- Trial name
- NCT01071850
- Testing
- ipragliflozin, Metformin
- Where
- 59 sites in United States, Colombia and 3 more
- Volunteers
- 412 people
- Sponsor
- Astellas Pharma Inc
Chronic Lymphocytic Leukemia, Leukemia
A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia
Dasatinib and lenalidomide are both prescribed for use in patients with different cancers of the blood. This study is experimental because neither drug has been approved by the Food and Drug Administration for the treatment of…
- Trial name
- NCT00829647
- Testing
- dasatinib and lenalidomide
- Sponsor
- Scripps Health
Pancreatic Cancer
TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer
This is a Phase I/II study evaluating the intraperitoneal delivery of TROP2 CAR/IL-15 TGFBR2 KO NK cells in combination with oral belzutifan (120 mg daily) for patients with recurrent, locally advanced, unresectable and…
- Trial name
- NCT07377526
- Testing
- TGFBR2 KO CAR27/IL-15 NK cells
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
Healthy
A Phase I, Open Interaction Study Between GLPG1837 and Midazolam in Healthy Male Subjects
This will be a drug-drug interaction study to evaluate the effect of multiple oral doses of GLPG1837 on the single dose pharmacokinetic profile of midazolam administered in fed healthy male subjects.
- Trial name
- NCT02562950
- Testing
- GLPG1837 500 mg, Midazolam, GLPG1837 1000 mg
- Where
- Belgium
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Lakefront Biotherapeutics NV
ER-positive, HER2-negative Breast Cancer
A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833
The Sponsor is developing the test medicine, AZD9833 for the potential treatment of estrogen receptor (ER)-positive breast cancer.
- Trial name
- NCT05364255
- Testing
- [14C]AZD9833 Oral Solution, 75 mg
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Post-menopausal Osteoporosis
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of PTH134 in Post-menopausal Women
This study is designed to provide information about the bone-anabolic response of PTH134 when administered orally, in comparison to Forsteo®, the sub-cutaneous form of teriparatide, the active ingredient in PTH134.
- Trial name
- NCT01224717
- Testing
- PTH134, Forsteo
- Where
- 4 sites in Denmark, Germany
- Volunteers
- 104 people
- Sponsor
- Novartis
Healthy
Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD2423 Multiple Doses in Healthy Volunteers
Three-part study investigating the safety and tolerability of AZD2423 multiple doses in 98 healthy volunteers: Part 1 80 young and elderly subjects in a parallel, double blind, randomised study.
- Trial name
- NCT00977626
- Testing
- Part 2 - AZD2423, Part 3 - AZD2423
- Where
- United Kingdom
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteers
A Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototypic Inhibitor of Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 on the Single-Dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants
The purpose of this study is to evaluate the effect of single dose intravenous rifampin on the single-dose PK of orally administered TAK-906.
- Trial name
- NCT04121078
- Testing
- TAK-906, Rifampin
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Millennium Pharmaceuticals, Inc.
Head and Neck Cancer
A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer
This is a Phase 1 / Phase 2 study of newly diagnosed patients with biopsy-proven head and neck cancer (squamous cell carcinoma) who are undergoing standard radiation therapy and treatment with cisplatin.
- Trial name
- BMX-HN (NCT02990468)
- Testing
- BMX-001, Radiation Therapy, Cisplatin
- Where
- 4 sites in United States
- Volunteers
- 29 people
- Sponsor
- BioMimetix JV, LLC
Healthy
Relative Bioavailability of BI 44847 in Different Ethnic Groups and Evaluation of Effect of Diet and Acarbose Coadministration on Bioavailability Following Oral Administration of 200 mg BI 44847 in Healthy Male Volunteers
The objectives were to investigate the relative bioavailability of BI 44847 in different racial groups (white, Asian, and African subjects) and to investigate the effect of different types of diet and acarbose coadministration on…
- Trial name
- NCT02211950
- Testing
- BI 44847, Acarbose, Japanese diet
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Adjunctive Treatment of Major Depressive Disorder (MDD)
A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder
The study is a Phase 2, double-blind, randomized, placebo-controlled study in Major Depressive Disorder (MDD) participants with an inadequate response to standard antidepressants The objective of the study is to assess CLE-100…
- Trial name
- SOLEO (NCT06340958)
- Testing
- CLE-100
- Where
- 23 sites in United States
- Volunteers
- 99 people
- Sponsor
- Clexio Biosciences Ltd.
Type 1 Diabetes Mellitus
Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes
The purpose of this study is to determine if adding dapagliflozin to insulin is a safe and effective therapy to improve glycemic control in patients with type 1 diabetes.
- Trial name
- DEPICT 2 (NCT02460978)
- Testing
- Dapagliflozin
- Where
- 136 sites in United States, Argentina and 11 more
- Volunteers
- 815 people
- Sponsor
- AstraZeneca
Head and Neck Cancer
S9902 Docetaxel Plus Carboplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of docetaxel plus carboplatin in treating patients who…
- Trial name
- NCT00003908
- Testing
- carboplatin, docetaxel
- Where
- 85 sites in United States
- Volunteers
- 68 people
- Sponsor
- SWOG Cancer Research Network
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.